Rhea-AI Summary
Cepheid (NASDAQ:CPHD) announced CE marking under the EU IVDR for its Xpert GI Panel, a multiplex PCR test for 11 gastrointestinal pathogens from one stool sample in Cary-Blair media.
The test runs on 10‑color GeneXpert systems, delivers results in about 74 minutes, and will ship soon to CE-mark countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Cepheid (NASDAQ: CPHD) was selected by the U.S. Centers for Disease Control and Prevention as one of four national collaborators under a new federal IDIQ awarded Feb 18, 2026 to speed rapid diagnostic development for public health emergencies.
The collaboration gives Cepheid early access to outbreak samples, genomic sequences, and reference materials to accelerate next‑generation assay development and deployment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags